Vaccí contra la COVID-19: diferència entre les revisions
Contingut suprimit Contingut afegit
m neteja i estandardització de codi |
|||
Línia 36:
|+Vacunes homologades per a ús d’emergència o amb autorització plena
|- valign="top"
!Vacunes<br />desenvolupadors, patrocinadors
!Tecnologia
!Fase actual<br />(participants)<br />Disseny
!Fase finalitzada{{efn-la|Última fase amb resultats publicats.}} (participants)<br />Resposta immunitària
!Autorització
|- valign="top"
|'''[[Tozinameran]]'''<wbr /><ref name="hcreg">{{ref-web|data=9 desembre 2020|títol=Regulatory Decision Summary – Pfizer-BioNTech COVID-19 Vaccine|url=https://covid-vaccine.canada.ca/info/regulatory-decision-summary-detailTwo.html?linkID=RDS00730|access-date=9 desembre 2020|editor=Health Canada, Government of Canada}}</ref><ref name="NCT04368728">{{ref-web|títol=Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults |url=https://clinicaltrials.gov/ct2/show/NCT04368728 |website=[[ClinicalTrials.gov]] |editor=[[United States National Library of Medicine]] |type=Registry |id=NCT04368728 |data= 30 abril 2020 |access-date= 14 juliol 2020 |archive-date= 11 octubre 2020 |archive-url=https://web.archive.org/web/20201011084828/https://clinicaltrials.gov/ct2/show/NCT04368728/ |url-status=live }}</ref><ref name="EudraCT-2020-001038-36">{{ref-web|títol=A Multi-site Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults |url=https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001038-36/DE |website=EU Clinical Trials Register |editor=European Union |type=Registry |id=[[EudraCT]] 2020-001038-36 |data= 14 abril 2020 |access-date= 22 abril 2020 |archive-url=https://web.archive.org/web/20200422111024/https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001038-36/DE |archive-date= 22 abril 2020 |url-status=live}}</ref><br />[[BioNTech]], [[Pfizer]], [[Fosun Pharma]]
Linha 54 ⟶ 50:
Els resultats positius d’una anàlisi provisional es van anunciar el 18 de novembre de 2020<ref>{{ref-web|cognom1=Lovelace Jr. |nom1=Berkeley |títol=Pfizer says final data analysis shows Covid vaccine is 95% effective, plans to submit to FDA in days |url=https://www.cnbc.com/2020/11/18/coronavirus-pfizer-vaccine-is-95percent-effective-plans-to-submit-to-fda-in-days.html |website=CNBC |data= 18 novembre 2020 |name-list-style=vanc}}</ref> i es van publicar el 10 de desembre de 2020 amb una eficàcia global del 95%.<ref>{{ref-web|títol=Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in ''The New England Journal of Medicine'' |url=https://www.businesswire.com/news/home/20201210005703/en/ |editor=Pfizer | via=Business Wire |access-date=11 desembre 2020}}</ref><ref>{{ref-web| url=https://www.fda.gov/media/144337/download | títol=FDA Review of Efficacy and Safety of Pfizer-BioNTech COVID-19 Vaccine Emergency Use Authorization Request | editor=U.S. [[Food and Drug Administration]] (FDA) | data= 10 desembre 2020 | llengua=anglès|consulta= 26 desembre 2020}} {{PD-notice}}</ref>|locations=Alemanya, EUA|duration=Jul{{nbsp}}2020 – Nov{{nbsp}}2020<ref>{{ref-notícia|títol=Pfizer ends COVID-19 trial with 95% efficacy, to seek emergency-use authorization|url=https://www.reuters.com/article/health-coronavirus-vaccines-pfizer/pfizer-ends-covid-19-trial-with-95-efficacy-to-seek-emergency-use-authorization-idUSL4N2HZ3VS|nom=Michael |cognom=Erman |access-date= 18 novembre 2020|obra=Reuters|data= 18 novembre 2020}}</ref><ref name="NYT-20201120">{{ref-notícia|cognom=Zimmer |nom=Carl |enllaçautor=Carl Zimmer |títol=2 Companies Say Their Vaccines Are 95% Effective. What Does That Mean? You might assume that 95 out of every 100 people vaccinated will be protected from Covid-19. But that's not how the math works. |url=https://www.nytimes.com/2020/11/20/health/covid-vaccine-95-effective.html |data= 20 novembre 2020 |obra=[[The New York Times]] |access-date= 21 novembre 2020 }}</ref>}}
|{{ClinicalStudyInfo|align=left|phase=1|endphase=2|participants=60|description=Resposta forta al domini d'unió al receptor de la [[Immunoglobulina G|IgG]] i l'[[anticòs neutralitzant]], assolint la resposta màxima als 7 dies després d'una [[dosi de reforç]], robusta pels [[limfòcits T]] CD4+ i CD8+, de durabilitat indeterminada.<ref>{{ref-notícia|cognom=Tiggle|nom=Nick|títol=Covid-19 vaccine: Allergy warning over new jab|url= https://www.bbc.co.uk/news/health-55244122 |data=9 desembre 2020|obra=BBC News|access-date=9 desembre 2020}}</ref><ref>{{ref-publicació|cognom1=Mulligan |nom1=Mark J. |cognom2=Lyke |nom2=Kirsten E. |cognom3=Kitchin |nom3=Nicholas |cognom4=Absalon |nom4=Judith |cognom5=Gurtman |nom5=Alejandra |cognom6=Lockhart |nom6=Stephen |cognom7=Neuzil |nom7=Kathleen |cognom8=Raabe |nom8=Vanessa |cognom9=Bailey |nom9=Ruth |last10=Swanson |first10=Kena A. |last11=Li |first11=Ping |last12=Koury |first12=Kenneth |last13=Kalina |first13=Warren |last14=Cooper |first14=David |last15=Fontes-Garfias |first15=Camila |last16=Shi |first16=Pei-Yong |last17=Türeci |first17=Özlem |last18=Tompkins |first18=Kristin R. |last19=Walsh |first19=Edward E. |last20=Frenck |first20=Robert |last21=Falsey |first21=Ann R. |last22=Dormitzer |first22=Philip R. |last23=Gruber |first23=William C. |last24=Şahin |first24=Uğur |last25=Jansen |first25=Kathrin U. | display-authors=6 |títol=Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults |doi-access=free |publicació=Nature |pàgines=589–593 |doi=10.1038/s41586-020-2639-4 |data= octubre 2020 |volum=586 |exemplar=7830 |pmid=32785213 |s2cid=221126922 |name-list-style=vanc }}</ref>|duration=May.{{nbsp}}2020 –}}
|{{Collapsible list|title=Emergència (21)
| [[Regne Unit|RU]]<ref name="ukgov12-2">{{ref-web|títol=UK medicines regulator gives approval for first UK COVID-19 vaccine |url=https://www.gov.uk/government/news/uk-medicines-regulator-gives-approval-for-first-uk-covid-19-vaccine |editor=Medicines and Healthcare Products Regulatory Agency, Government of the UK |access-date=2 desembre 2020 |data=2 desembre 2020}}</ref><ref name="MHRA 2020-12-08">{{ref-web|títol=Information for Healthcare Professionals on Pfizer/BioNTech COVID-19 vaccine | website=Medicines & Healthcare products Regulatory Agency (MHRA) |data=8 desembre 2020 | url=https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19/information-for-healthcare-professionals-on-pfizerbiontech-covid-19-vaccine | access-date=13 desembre 2020}}</ref><ref>{{ref-web|títol=Conditions of Authorisation for Pfizer/BioNTech COVID-19 vaccine | website=Medicines & Healthcare products Regulatory Agency (MHRA) |data=3 desembre 2020 | url=https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19/conditions-of-authorisation-for-pfizerbiontech-covid-19-vaccine | access-date=13 desembre 2020}}</ref>
| [[Bahrain]]<ref>{{ref-web|títol=Bahrain becomes second country to approve Pfizer COVID-19 vaccine |url=https://www.aljazeera.com/news/2020/12/4/bahrain-becomes-second-country-to-approve-pfizer-covid-19-vaccine |website=[[Al Jazeera]] |access-date=5 desembre 2020}}</ref>
| [[Canadà]]<ref name="hcreg"/><ref name="hcapps">{{ref-web|data=9 desembre 2020|títol=Drug and vaccine authorizations for COVID-19: List of applications received|url=https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/authorization/applications.html|consulta=9 desembre 2020|editor=Health Canada, Government of Canada}}</ref>
| [[EUA]]<ref>{{cite press release | title=FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine | publisher=U.S. [[Food and Drug Administration]] (FDA) | date=11 desembre 2020 | url=https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19 | access-date=11 desembre 2020}} {{PD-notice}}</ref><ref>
{{ref-web|títol=Pfizer-BioNTech COVID-19 Vaccine EUA Fact Sheet for Healthcare Providers |editor=Pfizer |data=11 desembre 2020 | url=https://www.fda.gov/media/144413/download | format=PDF}}</ref>
}}
{{Collapsible list|title=Plena (9)
| [[Aràbia Saudí]]<ref>{{ref-web|data=10 desembre 2020|títol=Coronavirus: Saudi Arabia approves Pfizer COVID-19 vaccine for use|url=https://english.alarabiya.net/en/coronavirus/2020/12/10/Coronavirus-Saudi-Arabia-approves-Pfizer-COVID-19-vaccine-for-use|access-date=10 desembre 2020|website=Al Arabiya English}}</ref><ref>{{ref-notícia|cognom1=Zimmer|nom1=Carl|cognom2=Corum|nom2=Jonathan|cognom3=Wee|nom3=Sui-Lee|data=2020-06-10|títol=Coronavirus Vaccine Tracker|obra=The New York Times|url=https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html|access-date=12 desembre 2020|issn=0362-4331}}</ref>
| [[Suïssa]]<ref name="Swiss authorization">{{cite press release |title=Swissmedic grants authorisation for the first COVID-19 vaccine in Switzerland |url=https://www.bag.admin.ch/bag/en/home/das-bag/aktuell/medienmitteilungen.msg-id-81761.html |publisher=Swiss Agency for Therapeutic Products (Swissmedic) |date=19 desembre 2020 |access-date=19 desembre 2020}}</ref>
| [[Noruega]]<ref name=">Norwegian authorization">{{cite press release |title=Koronavaksinen fra BioNTech og Pfizer (Comirnaty) får betinget godkjenning i Europa. |url=https://legemiddelverket.no/nyheter/status-pa-koronavaksiner-under-godkjenning-per-211220 |publisher=Statens legemiddelverk |date=21 desembre 2020 |access-date=25 desembre 2020}}</ref>
| [[Illes Faroe]]<ref name="Danish authorization">{{ref-web|títol=Første vaccine mod COVID19 godkendt i EU|url=https://laegemiddelstyrelsen.dk/da/nyheder/2020/foerste-vaccine-mod-covid19-godkendt-i-eu/|access-date=2020-12-26|website=Lægemiddelstyrelsen|llengua=da-DK}}</ref>
| [[Groenlàndia]]<ref name="Danish authorization"/>
| [[Sèrbia]]<ref>{{ref-notícia|url=https://balkaninsight.com/2020/12/21/serbia-leads-region-in-expecting-covid-19-vaccines-within-days/|obra=BalkanInsight |data=21 desembre 2020 |títol=Serbia leads region in expecting COVID-19 vaccines within days|consulta=26 desembre 2020}}</ref><ref>{{ref-notícia|url=https://www.srbija.gov.rs/vest/en/165409/first-shipment-of-pfizer-biontech-vaccine-arrives-in-serbia.php|obra=Serbian government website|data=22 desembre 2020 |títol= First shipment of Pfizer-BioNTech vaccine arrives in Serbia|consulta=26 desembre 2020}}</ref><ref>{{ref-notícia|url=https://europeanwesternbalkans.com/2020/12/24/serbia-has-started-vaccination-against-coronavirus/|obra=European Western Balkans |data=24 desembre 2020 |títol=Serbia has started vaccination against coronavirus|consulta=26 desembre 2020}}</ref>
| [[Malàisia]]<ref>{{ref-notícia|cognom= Lim
|nom= Ida
|data= 2021-01-08
Linha 99 ⟶ 93:
}}
|- valign="top"
|'''[[mRNA-1273]]'''<wbr /><ref name="NCT04470427">{{ref-web|títol=A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04470427 |website=[[ClinicalTrials.gov]] |editor=[[United States National Library of Medicine]] |type=Registry |id=NCT04470427 |data= 14 juliol 2020 |access-date= 27 juliol 2020}}</ref><ref name="palca">{{ref-notícia|cognom1=Palca |nom1=Joe |títol=COVID-19 vaccine candidate heads to widespread testing in U.S. |url=https://www.npr.org/sections/coronavirus-live-updates/2020/07/27/895672859/us-vaccine-candidate-heads-to-widespread-testing-in-people |consulta= 27 juliol 2020 |obra=NPR |data= 27 juliol 2020 | name-list-format = vanc }}</ref><br />[[Moderna]], [[National Institute of Allergy and Infectious Diseases|NIAID]], [[Biomedical Advanced Research and Development Authority|BARDA]], [[Coalició per a les Innovacions en Preparació per Epidèmies|CEPI]]
|[[Vacuna d'ARN|V. d'ARN]] (dispersió de [[Nanopartícula lipídica sòlida|nanopartícules lipídiques]]) contenint [[ARNmod]]
|{{ClinicalStudyInfo|align=left|phase=3|participants=30000|description=Intervencional; estudi aleatori, controlat amb placebo, per a l'eficàcia, la seguretat i la immunogenicitat. El 15 de novembre de 2020 es van anunciar resultats positius d’una anàlisi provisional.<ref>{{ref-web|títol=Promising Interim Results from Clinical Trial of NIH-Moderna COVID-19 Vaccine |url=https://www.nih.gov/news-events/news-releases/promising-interim-results-clinical-trial-nih-moderna-covid-19-vaccine |website=National Institutes of Health (NIH) |data= 15 novembre 2020}}</ref>|locations=EUA|duration=Jul 2020{{snd}}Oct 2022}}
|{{ClinicalStudyInfo|align=left|phase=1|endphase=2|participants=720|references=<ref>{{ref-publicació|cognom=National Institute of Allergy and Infectious Diseases (NIAID)|data=2020-12-03|títol=Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults|url=https://clinicaltrials.gov/ct2/show/NCT04283461|publicació= Clinial Trials|llengua=anglès|consulta= 26 desembre 2020}}</ref><ref>{{ref-web|títol=Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older |url=https://clinicaltrials.gov/ct2/show/NCT04405076|access-date=19 desembre 2020|website=ClinicalTrials.gov }}</ref>|description=Resposta d’anticossos neutralitzants dependents de la dosi segons el programa de dues dosis; durabilitat indeterminada.<ref>{{ref-publicació|cognom=Widge |nom=Alicia T. |cognom2=Rouphael |nom2=Nadine G. |cognom3=Jackson |nom3=Lisa A. |cognom4=Anderson |nom4=Evan J. |cognom5=Roberts |nom5=Paul C. |cognom6=Makhene |nom6=Mamodikoe |cognom7=Chappell |nom7=James D. |cognom8=Denison |nom8=Mark R. |cognom9=Stevens |nom9=Laura J. | last10=Pruijssers | first10=Andrea J. | last11=McDermott | first11=Adrian B. | last12=Flach | first12=Britta | last13=Lin | first13=Bob C. | last14=Doria-Rose | first14=Nicole A. | last15=O’Dell | first15=Sijy | last16=Schmidt | first16=Stephen D. | last17=Neuzil | first17=Kathleen M. | last18=Bennett | first18=Hamilton | last19=Leav | first19=Brett | last20=Makowski | first20=Mat | last21=Albert | first21=Jim | last22=Cross | first22=Kaitlyn | last23=Edara | first23=Venkata-Viswanadh | last24=Floyd | first24=Katharine | last25=Suthar | first25=Mehul S. | last26=Buchanan | first26=Wendy | last27=Luke | first27=Catherine J. | last28=Ledgerwood | first28=Julie E. | last29=Mascola | first29=John R. | last30=Graham | first30=Barney S. | last31=Beigel | first31=John H. | name-list-style=vanc | display-authors=6 |títol=Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination |publicació=New England Journal of Medicine |editorial=Massachusetts Medical Society |data=3 desembre 2020 | issn=0028-4793 | doi=10.1056/nejmc2032195 |pàgina=}}</ref><ref name="jackson">{{ref-publicació|vauthors=Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott A, Flach B, Doria-Rose NA, Corbett KS, Morabito KM, O'Dell S, Schmidt SD, Swanson PA, Padilla M, Mascola JR, Neuzil KM, Bennett H, Sun W, Peters E, Makowski M, Albert J, Cross K, Buchanan W, Pikaart-Tautges R, Ledgerwood JE, Graham BS, Beigel JH |collaboration=mRNA-1273 Study Group |display-authors=6 |títol=An mRNA Vaccine against SARS-CoV-2 – Preliminary Report |publicació=New England Journal of Medicine |data= juliol 2020 |volum=383 |exemplar=20 |pàgines=1920–1931 |doi=10.1056/NEJMoa2022483 |doi-access=free |pmid=32663912 |pmc=7377258 |lay-url=https://www.statnews.com/2020/07/14/moderna-covid19-vaccine-first-data-show-spurs-immune-response/ }}</ref><ref name="jackson-app">{{ref-publicació|vauthors=Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott A, Flach B, Doria-Rose NA, Corbett KS, Morabito KM, O'Dell S, Schmidt SD, Swanson PA, Padilla M, Mascola JR, Neuzil KM, Bennett H, Sun W, Peters E, Makowski M, Albert J, Cross K, Buchanan W, Pikaart-Tautges R, Ledgerwood JE, Graham BS, Beigel JH |collaboration=mRNA-1273 Study Group |display-authors=6 |títol=An mRNA Vaccine against SARS-CoV-2 – Preliminary Report Supplementary appendix |publicació=New England Journal of Medicine |data= juliol 2020 |doi=10.1056/NEJMoa2022483 |doi-access=free |pmid=32663912 }}</ref>|locations=EUA|duration=Mar 2020{{snd}}Nov 2021}}
|{{Collapsible list|title=Emergència (4)
| [[EUA]]<ref>{{cite press release | title=FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine | website=U.S. [[Food and Drug Administration]] (FDA) | url=https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid | access-date=18 desembre 2020}}</ref>
| [[Canadà]]<ref name="hc-moderna12-23">{{ref-web|títol=Regulatory Decision Summary - Moderna COVID-19 Vaccine - Health Canada |url=https://covid-vaccine.canada.ca/info/regulatory-decision-summary-detailTwo.html?linkID=RDS00736 |editor=Health Canada, Government of Canada |access-date=23 desembre 2020 |data=23 desembre 2020}}</ref><ref name="hcapps" />
| [[Regne Unit]]<ref>{{ref-web|títol=Information for Healthcare Professionals on COVID-19 Vaccine Moderna | website=[[Medicines and Healthcare products Regulatory Agency]] (MHRA) |data= 8 gener 2021 | url=https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-moderna/information-for-healthcare-professionals-on-covid-19-vaccine-moderna | access-date= 8 gener 2021}}</ref><ref>{{ref-web|títol=Conditions of Authorisation for COVID-19 Vaccine Moderna | website=[[Medicines and Healthcare products Regulatory Agency]] (MHRA) |data= 8 gener 2021 | url=https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-moderna/conditions-of-authorisation-for-covid-19-vaccine-moderna | access-date= 9 gener 2021}}</ref>
}}
{{Collapsible list|title=Plena (6)
| [[Unió Europea]]<ref name="EU approval">{{Cite press release|title=European Commission authorises second safe and effective vaccine against COVID-19|url=https://ec.europa.eu/commission/presscorner/detail/en/ip_21_3|access-date= 6 gener 2021|website=European Commission }}</ref><ref>{{cite press release|date= 6 gener 2021|title=EMA recommends COVID-19 Vaccine Moderna for authorisation in the EU|url=https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-moderna-authorisation-eu|access-date= 6 gener 2021|publisher=European Medicines Agency}}</ref>
| [[Noruega]]<ref>{{ref-web|títol=Status på koronavaksiner under godkjenning per 6. januar 2021|url=https://legemiddelverket.no/nyheter/status-pa-koronavaksiner-under-godkjenning-per-6-januar-2021|access-date=2021-01-07|website=Statens legemiddelverk|llengua=nb-NO}}</ref>
| [[Groenlàndia]]<ref name="Danish Moderna approval" />
| [[Suïssa]]<ref>{{cite news|url=https://www.srf.ch/news/schweiz/das-neuste-zur-coronakrise-swissmedic-erteilt-zulassung-fuer-moderna-impfstoff-in-der-schweiz |title=Swissmedic erteilt Zulassung für Moderna-Impfstoff in der Schweiz |publisher=SRF |date=2020-01-12 |accessdate=2020-01-12}}</ref><ref>{{cite press release|title=Swissmedic grants authorisation for the COVID-19 vaccine from Moderna |url=https://www.swissmedic.ch/swissmedic/en/home/news/coronavirus-covid-19/zulassung-covid-19-impfstoff-moderna.html |website=Swissmedic |date=2020-01-12 |accessdate=2020-01-12}}</ref>
}}
|- valign="top"
|'''[[AZD1222]]'''<wbr />{{efn-la|[[Serum Institute of India]] produirà la vacuna ''ChAdOx1{{nbsp}}nCoV-19'' per l'Índia<ref>{{ref-notícia|url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/astrazeneca-serum-institute-of-india-sign-licensing-deal-for-1-billion-doses-of-oxford-vaccine/articleshow/76202016.cms|títol=AstraZeneca & Serum Institute of India sign licensing deal for 1 million doses of Oxford vaccine|obra=The Economic Times|access-date= 15 juny 2020}}</ref> and other low and middle income countries.<ref>{{ref-notícia|títol=Covid-19 vaccine: Serum Institute signs up for 100 million doses of vaccines for India, low and middle-income countries |url=https://www.financialexpress.com/lifestyle/health/covid-19-vaccine-serum-institute-signs-up-for-100-million-doses-of-vaccines-for-india-low-and-middle-income-countries/2047884/ |obra=The Financial Express |data= 7 agost 2020}}</ref>}}{{efn-la|Nom d'Oxford: ''ChAdOx1{{nbsp}}nCoV-19''. La fabricació al Brasil la realitzarà [[Oswaldo Cruz Foundation]].<ref>{{ref-notícia|cognom1=Walsh |nom1=Nick |cognom2=Shelley |nom2=Jo |cognom3=Duwe |nom3=Eduardo |cognom4=Bonnett |nom4=William |data= 27 juliol 2020 |títol=The world's hopes for a coronavirus vaccine may run in these health care workers' veins |url=https://edition.cnn.com/2020/07/27/americas/brazil-covid-19-sinovac-vaccine-intl/index.html |editorial=[[CNN]] |lloc=[[São Paulo]] |access-date= 3 agost 2020 |name-list-style=vanc |archive-date= 3 agost 2020 |archive-url=https://web.archive.org/web/20200803211040/https://edition.cnn.com/2020/07/27/americas/brazil-covid-19-sinovac-vaccine-intl/index.html |url-status=live }}</ref>}}<ref name="NCT04400838">{{ref-web|títol=Investigating a Vaccine Against COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04400838 |website=[[ClinicalTrials.gov]] |editor=[[United States National Library of Medicine]] |id=NCT04400838 |data= 26 maig 2020 |access-date= 14 juliol 2020 |archive-date= 11 octubre 2020 |archive-url=https://web.archive.org/web/20201011084750/https://clinicaltrials.gov/ct2/show/NCT04400838/ |url-status=live }}</ref><ref name="EudraCT-2020-001228-32">{{ref-web|url=https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001228-32/GB |títol=A Phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 |website=EU Clinical Trials Register |editor=European Union |id=[[EudraCT]] 2020-001228-32 |data= 21 abril 2020 |access-date= 3 agost 2020 |archive-date= 5 octubre 2020 |archive-url=https://web.archive.org/web/20201005201654/https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001228-32/GB |url-status=live }}</ref><ref name="ISRCTN89951424">{{ref-publicació|títol=A Phase III study to investigate a vaccine against COVID-19 |website=ISRCTN |id=ISRCTN89951424 |doi=10.1186/ISRCTN89951424 |data= 26 maig 2020 |cognom1=O'Reilly |nom1=Peter |name-list-style=vanc | doi-access=free }}</ref><br />[[Universitat d'Oxford]], [[AstraZeneca]], [[Coalició per a les Innovacions en Preparació per Epidèmies|CEPI]]
|[[Vector víric|Vector]] modificat d'[[adenovirus]] de [[ximpanzé]] (ChAdOx1)
|{{ClinicalStudyInfo|align=left|phase=3|participants=30000|description=Intervencional; [[Prova controlada aleatòria|estudi aleatoritzat controlat amb placebo]] sobre eficàcia, seguretat i immunogenicitat.<ref name="NCT04516746">{{ref-web|títol=A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04516746 |website=[[ClinicalTrials.gov]] |editor=[[United States National Library of Medicine]] |type=Registry |id=NCT04383574 |data= 12 maig 2020 |access-date= 26 agost 2020 |archive-date= 23 agost 2020 |archive-url=https://web.archive.org/web/20200823061231/https://clinicaltrials.gov/ct2/show/NCT04516746 |url-status=live }}</ref>
Els resultats positius d’una anàlisi provisional de quatre assaigs en curs es van anunciar el 23 de novembre de 2020 i es van publicar el 8 de desembre de 2020.<ref name="Voysey">{{ref-web| url = https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext |títol= Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK - The Lancet | format = | access-date =9 desembre 2020}}</ref> L'eficàcia general va ser del 70%, que va del 62% al 90% amb diferents règims de dosificació, amb un perfil de seguretat revisat per especialistes.<ref name = "Voysey" />|locations=Brasil (5.000),<ref>{{ref-web|títol=Trial of Oxford COVID-19 vaccine starts in Brazil |url=https://covid19vaccinetrial.co.uk/brazil-trial-launch |editor=[[Jenner Institute]] |access-date= 26 agost 2020 |archive-date= 9 setembre 2020 |archive-url=https://web.archive.org/web/20200909025948/https://covid19vaccinetrial.co.uk/brazil-trial-launch |url-status=live }}</ref> Regne Unit, Índia<ref>{{ref-notícia|títol=Oxford COVID-19 vaccine final trials will be held in these 17 hospitals in India |url=https://www.livemint.com/news/india/oxford-covid-19-vaccine-trials-will-be-held-in-these-17-hospitals-in-india-11597839519639.html |obra=mint |data= 19 agost 2020 }}</ref>|duration=maig 2020{{snd}}Aug 2021}}
|{{ClinicalStudyInfo|align=left|phase=1|endphase=2|participants=543|description=Anticossos específics per l'espiga el dia 28; [[anticòs neutralitzant|anticossos neutralitzants]] després d'una [[dosi de reforç]] al dia 56<ref name="folegatti">{{ref-publicació|cognom1=Folegatti |nom1=Pedro M |cognom2=Ewer |nom2=Katie J |cognom3=Aley |nom3=Parvinder K |cognom4=Angus |nom4=Brian |cognom5=Becker |nom5=Stephan |cognom6=Belij-Rammerstorfer |nom6=Sandra |cognom7=Bellamy |nom7=Duncan |cognom8=Bibi |nom8=Sagida |cognom9=Bittaye |nom9=Mustapha |last10=Clutterbuck |first10=Elizabeth A |last11=Dold |first11=Christina |last12=Faust |first12=Saul N |last13=Finn |first13=Adam |last14=Flaxman |first14=Amy L |last15=Hallis |first15=Bassam |last16=Heath |first16=Paul |last17=Jenkin |first17=Daniel |last18=Lazarus |first18=Rajeka |last19=Makinson |first19=Rebecca |last20=Minassian |first20=Angela M |last21=Pollock |first21=Katrina M |last22=Ramasamy |first22=Maheshi |last23=Robinson |first23=Hannah |last24=Snape |first24=Matthew |last25=Tarrant |first25=Richard |last26=Voysey |first26=Merryn |last27=Green |first27=Catherine |last28=Douglas |first28=Alexander D |last29=Hill |first29=Adrian V S |last30=Lambe |first30=Teresa |last31=Gilbert |first31=Sarah C |last32=Pollard |first32=Andrew J |display-authors=6 |author-link2=Katie Ewer |títol=Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial |publicació=Lancet |data= juliol 2020 |volum=396 |exemplar=10249 |pàgines=467–78 |doi=10.1016/S0140-6736(20)31604-4 |pmid=32702298 |pmc=7445431 |doi-access=free |lay-url=https://blogs.sciencemag.org/pipeline/archives/2020/07/20/new-data-on-the-oxford-az-vaccine |name-list-style=vanc }}</ref>}}
|{{Collapsible list|title=Emergència (21)
| [[Regne Unit]]<ref>{{ref-web|títol=Oxford University/AstraZeneca vaccine authorised by UK medicines regulator |url=https://www.gov.uk/government/news/oxford-universityastrazeneca-vaccine-authorised-by-uk-medicines-regulator |website=Gov.uk |editor=
Department of Health and Social Care|access-date=30 desembre 2020 |data=30 desembre 2020}}</ref>
| [[Argentina]]<ref>{{ref-web|títol=Argentine regulator approves AstraZeneca/Oxford COVID-19 vaccine |url=https://www.reuters.com/article/us-health-coronavirus-argentina-astrazen/argentine-regulator-approves-astrazeneca-oxford-covid-19-vaccine-astrazeneca-idUSKBN29421P |website=reuters.com |editor=
Reuters |access-date=30 desembre 2020 |data=30 desembre 2020}}</ref>
| [[Índia]]<ref name="NYT India">{{ref-notícia|nom=Emily |cognom=Schmall |nom2=Sameer |cognom2=Yasir |títol=India Approves Oxford-AstraZeneca Covid-19 Vaccine and 1 Other | website=The New York Times |data= 3 gener 2021 | url=https://www.nytimes.com/2021/01/03/world/asia/india-covid-19-vaccine.html | access-date= 3 gener 2021 | name-list-style=vanc}}</ref>
| [[El Salvador]]<ref>{{ref-notícia|títol=El Salvador greenlights AstraZeneca, Oxford University COVID-19 vaccine |url=https://www.reuters.com/article/us-health-coronavirus-el-salvador-vaccin/el-salvador-greenlights-astrazeneca-oxford-university-covid-19-vaccine-idINKBN2942HQ |editorial=Reuters |data=30 desembre 2020 }}</ref>
| [[República Dominicana]]<ref>{{ref-notícia|cognom1=Staff |nom1=Agencia EFE |títol=La República Dominicana aprueba la vacuna de AstraZeneca contra la covid-19 |url=https://www.efe.com/efe/america/sociedad/la-republica-dominicana-aprueba-vacuna-de-astrazeneca-contra-covid-19/20000013-4431079 |obra=Agencia EFE |data=31 desembre 2020 |llengua=es}}</ref>
| [[Mèxic]]<ref>{{ref-web|cognom=Sanitarios|nom=Comisión Federal para la Protección contra Riesgos|títol=AUTORIZACIÓN PARA USO DE EMERGENCIA A VACUNA ASTRAZENECA COVID-19|url=http://www.gob.mx/cofepris/articulos/autorizacion-para-uso-de-emergencia-a-vacuna-astrazeneca-covid-19?idiom=es|access-date=2021-01-05|website=gob.mx|llengua=es}}</ref>
| [[Bangladesh]]<ref>{{ref-web|títol=Oxford University-Astrazeneca vaccine: Bangladesh okays it for emergency use|url=https://www.thedailystar.net/frontpage/news/oxford-university-astrazeneca-vaccine-bangladesh-okays-it-emergency-use-2022381|access-date=2021-01-06|website=thedailystar.net|llengua=en}}</ref><ref>{{ref-web|títol=Bangladesh approves Oxford-AstraZeneca COVID-19 vaccine|url=https://www.aa.com.tr/en/asia-pacific/bangladesh-approves-oxford-astrazeneca-covid-19-vaccine/2099147|access-date=2021-01-06|website=aa.com.tr|llengua=en}}</ref>
}}
{{Collapsible list|title=Plena (0)
}}
|- valign="top"
|'''[[Gam-COVID-Vac]]'''<br />[[Institut Gamaleya de Recerca en Epidemiologia i Microbiologia]]; nom registrat: '''''Sputnik V'''''
|[[Vector viral]] No-[[Replicació vírica|replicatiu]]
|{{ClinicalStudyInfo|align=left|phase=3|participants=40000|description=Doble cec aleatoritzat, controlat amb placebo per avaluar l'eficàcia, la immunogenicitat i la seguretat<ref>{{ref-web|títol=Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04530396?term=vaccine&cond=covid-19&draw=3 |website=ClinicalTrials.gov |access-date= 11 setembre 2020 |archive-date= 12 setembre 2020 |archive-url=https://web.archive.org/web/20200912231654/https://clinicaltrials.gov/ct2/show/NCT04530396?term=vaccine&cond=covid-19&draw=3 |url-status=live }}</ref>|locations=Rússia, Índia<ref>{{ref-notícia|cognom1=Kumar |nom1=Shivani |títol=Sputnik-V from Russia arrives in India for clinal trials |url=https://www.hindustantimes.com/india-news/sputnik-v-from-russia-arrives-in-india-for-clinal-trials/story-b8k3Ecncxw2RBTrIxOiqxO.html |obra=Hindustan Times |data=1 desembre 2020 }}</ref><ref>{{ref-notícia|títol=Clinical trial: 17 volunteers given Russia's Sputnik V Covid-19 vaccine in Pune |url=https://indianexpress.com/article/india/clinical-trial-17-volunteers-given-russias-sputnik-v-covid-19-vaccine-in-pune-7094153/ |obra=The Indian Express |data=6 desembre 2020 }}</ref>|duration=Ago 2020 - Mai 2021}}
|{{ClinicalStudyInfo|align=left|phase=1|endphase=2|participants=76|description=Respostes dels [[anticossos neutralitzants]] i [[limfòcits T]].<ref name="logunov">{{ref-publicació|cognom1=Logunov |nom1=Denis Y |cognom2=Dolzhikova |nom2=Inna V |cognom3=others |títol=Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia |publicació=The Lancet |any=2020 |volum=396 |exemplar=10255 |pàgines=887–97 | issn=0140-6736 | doi=10.1016/s0140-6736(20)31866-3 | pmid=32896291 | pmc=7471804 | s2cid=221472251 | doi-access=free | name-list-style=vanc }}</ref>|locations=Rússia|duration=Jun 2020<ref name="logunov" /> - Set 2020}}
|{{Collapsible list|title=Emergència (21)
| [[Rússia]]<ref name="burki">{{ref-publicació| vauthors = Burki TK |títol= The Russian vaccine for COVID-19 |publicació= The Lancet. Respiratory Medicine |volum= 8 |exemplar= 11 |pàgines= e85–e86 |data= novembre 2020 | pmid = 32896274 | doi = 10.1016/S2213-2600(20)30402-1 | url = https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30402-1/fulltext | doi-access = free }}</ref>
| [[Bielorússia]]<ref>{{ref-notícia|títol=Belarus registers Sputnik V vaccine, in first outside Russia - RDIF |url=https://www.reuters.com/article/us-health-coronavirus-vaccine-belarus/belarus-registers-sputnik-v-vaccine-in-first-outside-russia-rdif-idINKBN28V0ZG |access-date=22 desembre 2020 |obra=Reuters |data=21 desembre 2020 }}</ref>
| [[Argentina]]<ref>[https://sputnikvaccine.com/newsroom/pressreleases/argentina-has-registered-the-sputnik-v-vaccine-based-on-russian-clinical-trial-data-/ ''Sputnik Vaccine Newsroom'']. 23 December 2020.</ref>>
| [[Bolívia]]<ref>{{ref-notícia|títol=Ministerio de Salud de Bolivia - Bolivia y Rusia firman contrato para adquirir 5,2 millones de dosis de la vacuna Sputnik-V contra la COVID-19 |url=https://www.minsalud.gob.bo/5114-bolivia-y-rusia-firman-contrato-para-adquirir-5-2-millones-de-dosis-de-la-vacuna-sputnik-v-contra-el-covid-19 |access-date= 1 gener 2021 |obra=www.minsalud.gob.bo}}</ref>
}}
{{Collapsible list|title=Plena (0)
}}
|- valign="top"
|'''[[CoronaVac]]'''<ref name="NCT04383574">{{ref-web|títol=Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection (COVID-19) (Renqiu) |url=https://clinicaltrials.gov/ct2/show/NCT04383574 |website=[[ClinicalTrials.gov]] |editor=[[United States National Library of Medicine]] |type=Registry |id=NCT04383574 |data= 12 maig 2020 |access-date= 14 juliol 2020}}</ref><ref name="NCname= nct04456595=">{{ref-web|url=https://clinicaltrials.gov/ct2/show/NCT04456595 |títol=Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals (PROFISCOV) |website=[[ClinicalTrials.gov]] |editor=[[United States National Library of Medicine]] |type=Registry |id=NCT04456595 |data= 2 juliol 2020 |access-date= 3 agost 2020}}</ref><ref>{{ref-publicació|cognom1=PT. Bio Farma |títol=A Phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-COV-2 inactivated vaccine in healthy adults aged 18-59 years in Indonesia |publicació=Registri Penyakit Indonesia |data= 10 agost 2020 |url=https://www.ina-registry.org/index.php?act=registry_trial_detail&code_trial=16202009080721WXFM0YX |consulta= 15 agost 2020}}</ref><br />[[Sinovac Biotech|Sinovac]]
|[[Vacuna inactivada|Inactivada]] [[SARS-CoV-2]]
|{{ClinicalStudyInfo|align=left|phase=3|participants=33620|description=Doble cec, aleatoritzat i controlat amb placebo per avaluar l'eficàcia i la seguretat|locations=[[Brasil]] (15,000);<ref>{{ref-web|url=https://www.scmp.com/news/world/americas/article/3106177/tests-show-coronavirus-vaccine-chinas-sinovac-safe-says-brazils |títol=Archived copy |access-date= 29 octubre 2020 |archive-date= 29 octubre 2020 |archive-url=https://web.archive.org/web/20201029151527/https://www.scmp.com/news/world/americas/article/3106177/tests-show-coronavirus-vaccine-chinas-sinovac-safe-says-brazils |url-status=live }}</ref> [[Xile]] (3,000);<ref>{{ref-web|url=https://chilereports.cl/en/news/2020/08/04/chile-initiates-clinical-study-for-covid-19-vaccine |títol=Archived copy |access-date= 29 octubre 2020 |archive-date= 11 octubre 2020 |archive-url=https://web.archive.org/web/20201011190302/https://chilereports.cl/en/news/2020/08/04/chile-initiates-clinical-study-for-covid-19-vaccine |url-status=live }}</ref> [[Indonèsia]] (1,620); [[Turquia]] (13,000)<ref>{{ref-web|títol=Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial For Evaluation of Efficacy and Safety of SARS-CoV-2 Vaccine (Vero Cell), Inactivated |url=https://clinicaltrials.gov/ct2/show/NCT04582344 |editor=clinicaltrials.gov |data= 8 octubre 2020 |access-date= 22 octubre 2020 |archive-date= 20 octubre 2020 |archive-url=https://web.archive.org/web/20201020123218/https://clinicaltrials.gov/ct2/show/NCT04582344 |url-status=live }}</ref>|duration=Jul 2020 – Oct 2021 a Brasil; Ago 2020 – Gen 2021 a Indonèsia}}
|{{ClinicalStudyInfo|align=left|phase=2|participants=600|description=Immunogenicitat que provoca un 92% de seroconversió a dosis més baixes i un 98% a dosis més altes després de 14 dies<ref>{{ref-publicació|cognom1=Zhang |nom1=Yanjun |cognom2=Zeng |nom2=Gang |cognom3=Pan |nom3=Hongxing |cognom4=Li |nom4=Changgui |cognom5=Hu |nom5=Yaling |cognom6=Chu |nom6=Kai |cognom7=Han |nom7=Weixiao |cognom8=Chen |nom8=Zhen |cognom9=Tang |nom9=Rong |last10=Yin |first10=Weidong |last11=Chen |first11=Xin |last12=Hu |first12=Yuansheng |last13=Liu |first13=Xiaoyong |last14=Jiang |first14=Congbing |last15=Li |first15=Jingxin |last16=Yang |first16=Minnan |last17=Song |first17=Yan |last18=Wang |first18=Xiangxi |last19=Gao |first19=Qiang |last20=Zhu |first20=Fengcai | display-authors=6 |títol=Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial |publicació=The Lancet Infectious Diseases |data= novembre 2020 |volum=0 |doi=10.1016/S1473-3099(20)30843-4 |pmid=33217362 |s2cid=227099817 | doi-access=free |name-list-style=vanc }}</ref>|locations=Xina|duration=Mai 2020 -}}
|{{Collapsible list|title=Emergència (21)
| [[Xina]] (''aviat'')<ref>{{ref-notícia|títol=China prepares large-scale rollout of domestically-produced coronavirus vaccines|url=https://www.theglobeandmail.com/world/article-china-prepares-large-scale-rollout-of-domestically-produced|data=6 desembre 2020|access-date=7 desembre 2020|obra=The Globe and Mail|autor=Huizhong Wu}}</ref>
| [[Bolívia]]<ref>{{ref-web|títol=Bolívia autoriza uso de vacinas Sputnik V e CoronaVac contra covid-19 |url=https://noticias.uol.com.br/internacional/ultimas-noticias/2021/01/06/bolivia-autoriza-uso-de-vacinas-sputnik-v-e-coronavac-contra-covid-19.htm |website=noticias.uol.com.br |access-date= 6 gener 2021 |llengua=pt-br}}</ref>
| [[Indonèsia]]<ref name=StraitsTimes20210111>{{cite news |url=https://www.straitstimes.com/asia/se-asia/indonesia-grants-emergency-use-approval-to-sinovac-vaccine-local-trials-show-65 |title=Indonesia grants emergency use approval to Sinovac’s vaccine, local trials show 65% efficacy |last=Soeriaatmadja |first=Wahyudi |work=The Straits Times |date=2021-01-11 |accessdate=2021-01-11}}</ref><ref name=Tempo>{{cite news |title=BPOM Grants Emergency Use Authorization for Sinovac Vaccine |url=https://en.tempo.co/read/1422220/bpom-grants-emergency-use-authorization-for-sinovac-vaccine |work=[[Tempo (Indonesian magazine)|Tempo]] |date=2021-01-11 |accessdate=2021-01-11}}</ref>
| [[Turquia]]<ref>{{cite news |title=Turkey to begin COVID-19 vaccine jabs by this weekend |url=https://www.aa.com.tr/en/latest-on-coronavirus-outbreak/turkey-to-begin-covid-19-vaccine-jabs-by-this-weekend/2106366 |work=Anadolu |date=2021-01-11 |accessdate=2021-01-11}}</ref>
}}
{{Collapsible list|title=Plena (0)
}}
|- valign="top"
|'''[[BBIBP-CorV]]'''<wbr /><ref name="ChiCTR2000034780">{{ref-publicació|cognom1=Chen |nom1=Wei |cognom2=Al Kaabi |nom2=Nawal |títol=A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells) |publicació=Chinese Clinical Trial Registry |data= 18 juliol 2020 |url=http://www.chictr.org.cn/showprojen.aspx?proj=56651 |access-date= 15 agost 2020 |name-list-style=vanc }}</ref><br />[[China National Pharmaceutical Group|Sinopharm]]: Institut de Productes Biològics de Pequín, Institut de Productes Biològics de Wuhan
|[[Vacuna inactivada|Inactivada]] [[SARS-CoV-2]] ([[cèl·lules Vero]])
Linha 183 ⟶ 170:
Els Emirats Àrabs Units van anunciar resultats positius d’una anàlisi provisional el 9 de desembre de 2020 amb una eficàcia de 86%.<ref>{{ref-web|títol=UAE: Ministry of Health announces 86 per cent vaccine efficacy |url=https://gulfnews.com/uae/health/uae-ministry-of-health-announces-86-per-cent-vaccine-efficacy-1.1607490555571 |editor=GulfNews |access-date=9 desembre 2020 }}</ref><ref>{{ref-web|cognom1=Cornwell |nom1=Alexander |títol=UAE says Sinopharm vaccine has 86% efficacy against COVID-19 |url=https://www.reuters.com/article/health-coronavirus-emirates/update-1-uae-says-sinopharm-vaccine-has-86-efficacy-against-covid-19-idUSL1N2IP09V |editor=Reuters |access-date=9 desembre 2020 |data=9 desembre 2020}}</ref>|locations=[[Emirats Àrabs Units|EAU]], [[Bahrain]], [[Jordània]],<ref>{{ref-web|cognom1=Yang |nom1=Yunkai |títol=A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above |url=https://clinicaltrials.gov/ct2/show/NCT04510207 |website=[[ClinicalTrials.gov]] |access-date= 15 setembre 2020 |name-list-style=vanc |archive-date= 14 setembre 2020 |archive-url=https://web.archive.org/web/20200914040138/https://clinicaltrials.gov/ct2/show/NCT04510207 |url-status=live }}</ref> [[Argentina]],<ref>{{ref-web|títol=Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19) |url=https://clinicaltrials.gov/ct2/show/NCT04560881?term=vaccine&cond=covid-19&draw=2&rank=3 |website=[[ClinicalTrials.gov]] |access-date= 28 setembre 2020 }}</ref> [[Marroc]],<ref>{{ref-web|títol=A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells) |url=http://www.chictr.org.cn/showprojen.aspx?proj=62581 |website=www.chictr.org.cn |editor=Chinese Clinical Trial Register (ChiCTR) |access-date=15 desembre 2020}}</ref> [[Perú]]<ref>{{ref-web|títol=Bahrain allows Sinopharm COVID-19 vaccine candidate use in frontline workers|url=https://www.msn.com/en-au/lifestyle/wellbeing/bahrain-announces-emergency-approval-for-use-of-covid-19-vaccine-candidate/ar-BB1aEciR |access-date= 3 novembre 2020|website=MSN|agency=Reuters}}</ref>|duration=Jul 2020 – Jul 2021}}
|{{ClinicalStudyInfo|align=left|phase=1|endphase=2|participants=320|description=Anticossos neutralitzadors el dia 14 després de 2 injeccions<ref>{{ref-publicació|vauthors=Xia S, Duan K, Zhang Y, Zhao D, et al. |títol=Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials |publicació=JAMA |data= 13 agost 2020 |volum=324 |exemplar=10 |pàgines=951–960 |doi=10.1001/jama.2020.15543 |pmid=32789505 |pmc=7426884 |doi-access=free }}</ref>|locations=Xina|duration=Apr 2020 – Jun 2020}}
|{{Collapsible list|title=Emergència (2)
| [[Egipte]]<ref>http://xinhuanet.com/english/2021-01/03/c_139637781.htm</ref>
| [[Jordània]]<ref>{{ref-web|títol=First batch of Chinese Sinopharm vaccine arrives in Jordan |url=https://en.royanews.tv/news/24716/2021-01-10 |editor=Roya News |access-date= 9 gener 2021 |llengua=en}}</ref>
}}
{{Collapsible list|title=Plena (3)
| [[Emirats Àrabs Units|EAU]]<ref name="nyt-uae-wee-dec-12-2020">{{ref-notícia|cognom1=Wee |nom1=Sui-Lee |títol=Chinese Covid-19 Vaccine Gets Key Push, but Doubts Swirl |url=https://www.nytimes.com/2020/12/09/business/china-coronavirus-vaccine-united-arab-emirates.html |access-date=12 desembre 2020 |obra=[[The New York Times]] |data=9 desembre 2020}}</ref><ref>{{ref-notícia|nom1=Eva|cognom=Dou|nom=Paul|cognom2=Schemm|data=9 desembre 2020|consulta=9 desembre 2020|títol=Coronavirus vaccine from China's Sinopharm is 86% effective, UAE officials say|url=https://www.washingtonpost.com/world/asia_pacific/coronavirus-vaccine-china-sinopharm-uae/2020/12/09/b32390f0-383c-11eb-aad9-8959227280c4_story.html|obra=Washington Post|issn=0190-8286}}</ref><ref>{{ref-web|títol=Coronavirus: UAE authorises emergency use of vaccine for frontline workers|url=https://www.thenationalnews.com/uae/health/coronavirus-uae-authorises-emergency-use-of-vaccine-for-frontline-workers-1.1077680|access-date=2020-11-24|website=The National}}</ref>
| [[Bahrain]]
}}
|- valign="top"
|'''[[BBV152]]'''
[[Bharat Biotech]], [[Consell Indi d'Investigació Mèdica]]
Linha 204 ⟶ 188:
|{{ClinicalStudyInfo|align=left|phase=1|participants=375|description=Resposta per [[anticòs neutralitzant|anticossos neutralitzants]] dependent de la dosi segons el programa de dues dosis.<br /><ref>{{ref-publicació|cognom1=Ella |nom1=Raches |cognom2=Mohan |nom2=Krishna |cognom3=Jogdand |nom3=Harsh |cognom4=Prasad |nom4=Sai |cognom5=Reddy |nom5=Siddharth |cognom6=Sarangi |nom6=Vamshi Krishna |cognom7=Ganneru |nom7=Brunda |cognom8=Sapkal |nom8=Gajanan |cognom9=Yadav |nom9=Pragya |last10=Panda |first10=Samiran |last11=Gupta |first11=Nivedita |last12=Reddy |first12=Prabhakar |last13=Verma |first13=Savita |last14=Rai |first14=Sanjay |last15=Singh |first15=Chandramani |last16=Redkar |first16=Sagar |last17=Gillurkar |first17=Chandra Sekhar |last18=Kushwaha |first18=Jitendra Singh |last19=Rao |first19=Venkat |last20=Mohapatra |first20=Satyajit |last21=Guleria |first21=Randeep |last22=Ella |first22=Krishna |last23=Bhargava |first23=Balram |títol=Safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152: a phase 1, double-blind, randomised control trial |url=https://www.medrxiv.org/content/10.1101/2020.12.11.20210419v1 |publicació=[[medRxiv]] preprint |data=15 desembre 2020 |doi=10.1101/2020.12.11.20210419}}</ref>
Informes de fase II pendents<ref>{{ref-web|títol=Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers |url=https://clinicaltrials.gov/ct2/show/NCT04471519 |type=Registry |id=NCT04471519|website=ClinicalTrials.gov }}</ref>}}
|{{Collapsible list|title=Emergència (1)
| [[Índia]] (''supervisat'')<ref name="NYT India" /></small>
}}
{{Collapsible list|title=Plena (0)
}}
|- valign="top"
|'''EpiVacCorona'''<wbr/><ref name="NCT04527575">{{ref-web|títol=Study of the Safety, Reactogenicity and Immunogenicity of "EpiVacCorona" Vaccine for the Prevention of COVID-19 (EpiVacCorona) |url=https://clinicaltrials.gov/ct2/show/NCT04527575 |website=[[ClinicalTrials.gov]] |editor=[[United States National Library of Medicine]] |type=Registry |id=NCT04368988 |data= 22 setembre 2020 |access-date= 16 novembre 2020}}</ref><br />[[Centre Estatal de Recerca en Virologia i Biotecnologia VECTOR|Vector]]
|[[Vacuna peptídica|Vacuna basada en antígens peptídics]]<ref name="NCT04527575" />
Linha 221 ⟶ 204:
|duration=Jul 2020<ref name="NCT04527575" /> - Set 2020<ref>{{cite news |title=Over 1,400 volunteers get Russia's first EpiVacCorona vaccine jab |url=https://tass.com/society/1235115 |work=TASS |date=15 December 2020 |language=en}}</ref>
}}
|{{Collapsible list|title=Emergència (1)
| [[Rússia]]<ref>{{cite web | title = О регистрации вакцины ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора «ЭпиВакКорона» | website=Rospotrebnadzor |url = https://www.rospotrebnadzor.ru/region/rss/rss.php?ELEMENT_ID=15660 |date=14 October 2020 |language=ru}}</ref><ref>{{cite web | title = Russia’s EpiVacCorona vaccine post-registration trials started | publisher=The Pharma Letter |url = https://www.thepharmaletter.com/article/russia-s-epivaccorona-vaccine-post-registration-trials-started |date=18 November 2020 |language=en}}</ref>
}}
{{Collapsible list|title=Plena (0)
}}
|- valign="top"
|'''[[Ad5-nCoV]]'''<wbr /><br />[[CanSino Biologics|CanSinoBIO]], Institut de Biotecnologia de Pequín de l'[[Acadèmia de Ciències Mèdiques Militars]]
|[[Vector viral|Vector]] d'[[adenovirus]] [[Vacuna recombinant|recombinant]] [[Serotipus|tipus]] 5
|{{ClinicalStudyInfo|align=left|phase=3|participants=40000|description=multicèntric global, aleatoritzat, doble cec, controlat amb placebo per avaluar l'eficàcia, la seguretat i la immunogenicitat|locations=Xina, [[Argentina]], [[Xile]],<ref>{{ref-web|cognom1=Lazcano |nom1=Patricio |títol=Así funcionan las cuatro vacunas que se probarán en Chile |url=https://www.latercera.com/que-pasa/noticia/asi-funcionan-las-cuatro-vacunas-que-se-probaran-en-chile/AD22DRDA4REH5MRWGIAI7GQFSM/ |editor=La Tercera |access-date=15 desembre 2020 |data= 15 novembre 2020}}</ref> [[Mèxic]],<ref>{{ref-web|cognom1=Martinez |nom1=Ana Isabel |títol=CanSino Biologics delivers COVID-19 vaccine to Mexico for late-stage trial |url=https://ca.reuters.com/article/idUSKBN27J21V |editor=Reuters |access-date= 4 novembre 2020 |data= 3 novembre 2020}}</ref> [[Pakistan]],<ref>{{ref-web|cognom1=Ng |nom1=Eric |títol=China's CanSino trials Covid-19 vaccine in 'high disease burden' nations |url=https://www.scmp.com/business/companies/article/3107389/chinese-vaccine-developer-cansino-targets-high-disease-burden |editor=South China Morning Post |access-date= 4 novembre 2020 |data= 28 octubre 2020}}</ref> [[Rússia]],<ref name="NCT04540419">{{ref-web|títol=Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04540419 |website=[[ClinicalTrials.gov]] |editor=[[United States National Library of Medicine]] |type=Registry |id=NCT04540419 |data= 13 novembre 2020 |access-date= 17 novembre 2020}}</ref> [[Aràbia Saudita]]<ref>{{ref-web|cognom1=Nafisa |nom1=Eltahir |títol=CanSino to start Phase III trial of COVID-19 vaccine in Saudi |url=https://www.reuters.com/article/us-health-coronavirus-saudi-cansinobio/cansino-to-start-phase-iii-trial-of-covid-19-vaccine-in-saudi-idUSKCN2550L9 |editor=Reuters |access-date= 4 novembre 2020 |data= 9 agost 2020}}</ref><ref>{{ref-web|cognom1=Gou |nom1=Jinbo |títol=Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above |url=https://clinicaltrials.gov/ct2/show/NCT04526990 |website=[[ClinicalTrials.gov]] |access-date= 17 setembre 2020 |name-list-style=vanc |archive-date= 18 setembre 2020 |archive-url=https://web.archive.org/web/20200918142722/https://clinicaltrials.gov/ct2/show/NCT04526990 |url-status=live }}</ref>|duration=Mar. {{ndash}} Des. 2020, Xina; Set. 2020 {{ndash}} Des. 2021, Pakistan; Set. 2020 {{ndash}} Nov. 2020, Rússia<ref name="NCT04540419" />}}
|{{ClinicalStudyInfo|align=left|phase=2|participants=508|description=Respostes dels [[limfòcits T]] i dels anticossos neutralitzants.<ref name="zhu7-20">{{ref-publicació|cognom1=Zhu |nom1=Feng-Cai |cognom2=Guan |nom2=Xu-Hua |cognom3=Li |nom3=Yu-Hua |cognom4=Huang |nom4=Jian-Ying |cognom5=Jiang |nom5=Tao |cognom6=Hou |nom6=Li-Hua |cognom7=Li |nom7=Jing-Xin |cognom8=Yang |nom8=Bei-Fang |cognom9=Wang |nom9=Ling | last10=Wang | first10=Wen-Juan | last11=Wu | first11=Shi-Po | last12=Wang | first12=Zhao | last13=Wu | first13=Xiao-Hong | last14=Xu | first14=Jun-Jie | last15=Zhang | first15=Zhe | last16=Jia | first16=Si-Yue | last17=Wang | first17=Bu-Sen | last18=Hu | first18=Yi | last19=Liu | first19=Jing-Jing | last20=Zhang | first20=Jun | last21=Qian | first21=Xiao-Ai | last22=Li | first22=Qiong | last23=Pan | first23=Hong-Xing | last24=Jiang | first24=Hu-Dachuan | last25=Deng | first25=Peng | last26=Gou | first26=Jin-Bo | last27=Wang | first27=Xue-Wen | last28=Wang | first28=Xing-Huan | last29=Chen | first29=Wei | display-authors=6 |títol=Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial |publicació=Lancet |data= juliol 2020 |volum=396 |exemplar=10249 |pàgines=479–88 | issn=0140-6736 | doi=10.1016/s0140-6736(20)31605-6 | pmid=32702299 | doi-access=free | lay-url=https://blogs.sciencemag.org/pipeline/archives/2020/07/20/new-data-on-the-cansino-vaccine | name-list-style=vanc }}</ref>}}
|{{Collapsible list|title=Emergència (1)
}}
{{Collapsible list|title=Plena (0)
}}
|- valign="top"
|}
== Vacunes en assaig clínic i encara no aprovades ==
| |||